NYSE$ELAN
Elanco Animal Health Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Elanco reported Q4 2025 revenue of $1.14B and a net loss of $276M; adjusted EPS was $0.13.
Q4 2025 revenue was $1.14 billion (+12% reported, +9% organic constant currency). GAAP net loss was $276 million ($0.56 per share) on $155 million restructuring charges; adjusted net income was $64 million ($0.13 adjusted EPS). Pet Health revenue rose 11% and Farm Animal 12%, led by new products including Credelio Quattro and Zenrelia. Full-year 2026 guidance: revenue $4.95B–$5.02B (+4%–6% organic CC), adjusted EBITDA $955M–$985M, adjusted EPS $1.00–$1.06, innovation revenue target raised to $1.15B.
- Q4 revenue $1.14B (+9% organic CC); adjusted EPS $0.13.
- Pet Health $489M; Farm Animal $640M; restructuring $155M in Q4.
- FY 2025 revenue $4.72B; adjusted EBITDA $901M; net leverage 3.6x.
- FY 2026 innovation target $1.15B; leverage goal 3.1x–3.3x.
Headline financials
Revenue & EPS history
Elanco · Revenue · Quarterly
$1.14B
Revenue by segment
Elanco · $1.58B total across 5 segments · Q3 2023
- Farm Animal$561M—35.6%
- Pet Health$495M+5.1%31.4%
- Cattle$242M+3.9%15.4%
- Poultry$184M+15.7%11.7%
- Swine$93M+10.7%5.9%
Forward guidance
FY 2026 guidance: 4%–6% organic constant currency revenue growth, 6%–9% adjusted EBITDA growth, adjusted EPS $1.00–$1.06, and $1.15B innovation revenue with path to sub-3x leverage in 2027.
Tailwinds
- 10th consecutive quarter of underlying organic growth.
- Befrena approval and Big 6 blockbuster portfolio on track.
- Elanco Ascend targeting $200M–$250M EBITDA savings by 2030.
Headwinds
- Q4 GAAP loss from restructuring and impairment charges.
- Adjusted EPS $0.13 down 7% YoY in the quarter.
- Manufacturing footprint changes create near-term cash costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+2.0%
Avg return
Earnings day
+2.8%
Avg return
5 days after
+1.1%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+27.2%
Q1 2024
Best reaction
-16.3%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +13.9% | -5.6% | +2.6% | |
| Q4 2025 | +7.3% | +6.7% | -0.7% | |
| Q3 2025 | -4.2% | -1.0% | -2.7% | |
| Q1 2025 | +26.2% | +34.8% | +46.2% | |
| Q4 2024 | -3.7% | +0.5% | -2.7% | |
| Q3 2024 | +9.4% | +9.8% | -2.8% | |
| Q2 2024 | +5.3% | +12.6% | +21.9% | |
| Q1 2024 | +27.2% | +25.7% | +34.7% | |
| Q4 2023 | +0.5% | -2.1% | -1.2% | |
| Q3 2023 | +15.9% | +14.1% | +36.4% | |
| Q2 2023 | +7.0% | +4.5% | +2.7% | |
| Q1 2023 | -3.8% | -8.4% | -0.1% | |
| Q4 2022 | -6.9% | -11.0% | -33.1% | |
| Q3 2022 | -10.3% | +0.4% | -6.7% | |
| Q2 2022 | -1.6% | +3.3% | -23.9% | |
| Q1 2022 | -7.9% | -6.4% | +1.5% | |
| Q4 2021 | +8.2% | +12.4% | +3.3% | |
| Q3 2021 | +1.2% | +0.3% | -14.3% | |
| Q2 2021 | -16.3% | -12.3% | -4.2% | |
| Q1 2021 | +3.8% | +3.4% | +10.1% | |
| Q4 2020 | +2.8% | +9.0% | -9.8% | |
| Q3 2020 | -4.7% | -8.0% | -9.8% | |
| Q2 2020 | +11.7% | +17.3% | +37.7% | |
| Q1 2020 | -13.5% | -12.9% | +3.6% | |
| Q4 2019 | -0.7% | -1.4% | -42.5% | |
| Q3 2019 | -1.9% | -3.1% | -1.2% | |
| Q2 2018 | -4.8% | -1.3% | -4.6% | |
| Q2 2019 | -4.8% | -1.3% | -4.6% | |
| Q1 2019 | +6.1% | +3.9% | +4.1% | |
| Q4 2018 | -2.4% | -1.7% | -2.7% | |
| Q3 2018 | +3.7% | +3.7% | -1.9% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro